Israel Englander Vera Therapeutics, Inc. Transaction History

Millennium Management LLC

$175 Billion
Q1 2025

A detailed history of Israel Englander (Millennium Management LLC) transactions in Vera Therapeutics, Inc. stock. As of the latest transaction made, Millennium Management LLC holds 15,500 shares of VERA stock, worth $324,105. This represents 0.0% of its overall portfolio holdings.

Number of Shares

15,500

Previous 77,648 80.04%

Holding current value

$324,105

Previous $3.28 Million 88.67%

% of portfolio

0.0%

Previous 0.0%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	BUY	$24.02 - $43.22 $1.38 Million - $2.47 Million	57,246 Added 73.73%	134,894 $3.24 Million
Q4 2024 Feb 14, 2025	SELL	$38.64 - $49.75 $8.45 Million - $10.9 Million	-218,787 Reduced 73.81%	77,648 $3.28 Million
Q3 2024 Nov 14, 2024	BUY	$34.09 - $46.71 $8.97 Million - $12.3 Million	263,038 Added 787.61%	296,435 $13.1 Million
Q2 2024 Aug 14, 2024	SELL	$33.72 - $48.82 $47,005 - $68,055	-1,394 Reduced 4.01%	33,397 $1.21 Million
Q1 2024 May 15, 2024	BUY	$14.91 - $49.14 $518,733 - $1.71 Million	34,791 New	34,791 $1.5 Million
Q2 2023 Aug 14, 2023	SELL	$6.11 - $17.83 $9.49 Million - $27.7 Million	-1,553,662 Reduced 82.32%	333,689 $5.36 Million
Q1 2023 May 15, 2023	BUY	$5.41 - $18.3 $4.21 Million - $14.3 Million	778,702 Added 70.24%	1,887,351 $14.6 Million
Q4 2022 Feb 14, 2023	BUY	$15.74 - $22.19 $11.2 Million - $15.8 Million	711,721 Added 179.31%	1,108,649 $21.5 Million
Q3 2022 Nov 14, 2022	BUY	$13.27 - $22.31 $1.6 Million - $2.69 Million	120,685 Added 43.69%	396,928 $8.46 Million

Others Institutions Holding VERA

# of Institutions

196

Shares Held

63.9M

Call Options Held

723K

Put Options Held

186K

View Full List

About Vera Therapeutics, Inc.

Ticker VERA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 27,042,300
Market Cap $565M
Description
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with ...

More about VERA

Track Israel Englander's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.

Account